$AKRO News
Last published 4mo ago
- 4mo agoNXTCAKRONextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyGlobeNewswireAvere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient,
- 11mo agoAKRONovo Nordisk has completed its acquisition of Akero TherapeuticsGlobeNewswireBagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (NASDAQ:AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025,
- 1y agoAKROAkero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025GlobeNewswirePost-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis
- 1y agoAKROEXELLEGNSynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate ProgressGlobeNewswireDUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant
- 1y agoAKROAkero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 BillionGlobeNewswireShareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE
- 1y agoAKROAkero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics, Inc. (AKRO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoAKROAkero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASHGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePublished results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of
- 1y agoAKROAkero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePhase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations
- 1y agoAKROAkero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025GlobeNewswireAnalysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in
- 1y agoAKROAkero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of MedicineGlobeNewswireResults support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025
- 1y agoAKROAkero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics to Present at the BofA Securities 2025 Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROIARTMRCYVIRTLong-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law OfficeGlobeNewswirePHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed
- 1y agoAKROAkero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases
- 1y agoAKROINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero")
- 1y agoAKROINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero")
- 1y agoAKRODRVNIARTKYTXNotice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed
- 1y agoAKROAkero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the
- 1y agoAKROCROXDPZEXTRGrabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ)GlobeNewswirePHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to
- 1y agoAKROAkero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked
- 1y agoAKROAkero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked
- 1y agoAKROAkero Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked
- 1y agoAKROAkero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY StudyGlobeNewswireAmong patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT
- 1y agoAKROAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHGlobeNewswireInvestor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company
- 1y agoAKROAkero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLDGlobeNewswire-- 601 patients have been enrolled in the double-blind portion of the SYNCHRONY Real-World study since initiation in November 2023 -- -- Data from SYNCHRONY Real-World study anticipated in the first half of 2026 --
- 1y agoAKROAkero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 1y agoAKROAkero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024GlobeNewswire-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage
- 1y agoAKROAkero Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 2y agoAKROAkero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to
- 2y agoAUPHAPLSCMPITPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
- 2y agoAKROAkero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 2y agoAKROINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmPR NewswireMoore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc....
- 2y agoAKROAkero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases
- 2y agoAKROAkero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHGlobeNewswireOutcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing
- 2y agoAKROAkero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked
- 2y agoAKROAkero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL
- 2y agoAKROAPLSAUPHHRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential
- 2y agoAKROINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsGlobeNewswireNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ:AKRO)
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential
- 2y agoAKROLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswireNEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential